The sensor to participate in the 2nd Annual LifeSci Partners Genetics Symposium on June 29, 2022

Montpellier, France, June 24, 2022– (work wire) – Regulatory information:

Sensors (FR0012596468 – ALSEN) (Paris:ALSEN) A number one clinical-stage biotechnology firm that focuses on growing novel therapies for the restoration, remedy and prevention of listening to loss problems, is happy to announce the participation of CEO Nawal Ozren in LifeSci Companions 2second abbreviation The Annual Symposium on Genetic Medicines takes place roughly 28-29 June 2022.

CEO Nawal Ozren will share a chat with Jeff Goodenburg as a part of LifeSci Companions 2second abbreviation Annual Symposium on Genetic Medicineson June 29, 2022. To attend the dialogue, please register over right here. A aspect chat replay will probably be out there shortly after the presentation ends on the similar time Hyperlink.

Date: Wednesday 29 June 2022
subsequent to the fireside chat: 8.30 a.m. – 9 a.m. EST (2.30 p.m. – 3 p.m. CST)
OccasionLifeSci 2 . Companionssecond abbreviation Annual Symposium on Genetic Medicines

About Sensor

Sensorion is a number one clinical-stage biotechnology firm that focuses on growing new therapies to revive, deal with and stop listening to loss problems, a major unmet world medical want.

Sensorion has constructed a singular analysis and improvement know-how platform to develop its understanding of the pathophysiology and etiology of the interior ear, enabling it to pick one of the best targets and strategies for drug candidates. Her portfolio combines small molecule applications with a preclinical portfolio of interior ear genetic therapies.

Its scientific section portfolio contains one Part II product: SENS-401 (Arazasetron) progressing in a deliberate, proof-of-concept section II scientific examine of SENS-401 in cisplatin-induced ototoxicity (CIO) and with accomplice Cochlear Restricted, a examine of SENS-401 in Sufferers scheduled for cochlear implantation.

Sensorion has entered right into a broad strategic collaboration with the Pasteur Institute specializing in the genetics of audiology. It incorporates two gene remedy applications aimed toward correcting single-gene genetic types of deafness together with deafness attributable to a mutation within the gene coding for Otoferlin, and listening to loss related to a mutation within the GJB2 gene to handle vital listening to loss segments in adults and youngsters. The corporate can also be working to determine biomarkers to enhance the analysis of those underserved illnesses.

www.sensorion.com

a poster: sensor
inside: FR0012596468
mnemonic: ALSEEN

disclaimer

This press launch incorporates sure forward-looking statements relating to Sensorion and its enterprise. These forward-looking statements are based mostly on assumptions that Sensorion considers affordable. Nonetheless, there might be no assure that such forward-looking statements will probably be verified, that are topic to quite a few dangers, together with these set forth within the Full Yr 2021 Monetary Report revealed on April 28, 2022 and out there on our web site and to growing circumstances. Financial, Monetary Markets and Markets by which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers that aren’t but identified to Sensorion or not presently thought-about by Sensorion. The incidence of all or a part of these dangers may trigger Sensorion’s precise outcomes, monetary situations, efficiency or achievements to be materially completely different from such forward-looking statements. This press launch and the knowledge it incorporates don’t represent a suggestion to promote or subscribe or a solicitation of a suggestion to purchase or subscribe for the shares of Sensorion in any nation. Relaying this press launch in some international locations could represent a violation of native legal guidelines and laws. Any recipient of this press launch should inform themselves of and adjust to any such native restrictions.

View supply model on businesswire.com: https://www.businesswire.com/information/residence/20220623005695/ar/

Contacts

Investor Relations
Catherine Levo
Head of Investor Relations and Communication
+33 6 72 18 00 22
ir.contact@sensorion-pharma.com

Worldwide Media Relations
Consilium Strategic Communications
Mary Jane Elliott / Jessica Hodgson
+44 7739 788014
+44 7561 424788
Sensorion@consilium-comms.com